Hormones as a double-edged sword: the role of hormones in cancer progression and the potential of targeted hormone therapies.
Breast cancer
Estrogen
Hormonal therapy
Progesterone
Prostate cancer
Synergistic effect
Journal
Medical oncology (Northwood, London, England)
ISSN: 1559-131X
Titre abrégé: Med Oncol
Pays: United States
ID NLM: 9435512
Informations de publication
Date de publication:
14 Oct 2024
14 Oct 2024
Historique:
received:
14
08
2024
accepted:
20
09
2024
medline:
14
10
2024
pubmed:
14
10
2024
entrez:
14
10
2024
Statut:
epublish
Résumé
Cancer remains a significant cause of mortality in the world, with increasing prevalence worldwide. There are numerous treatments ranging from surgery to chemotherapy and radiotherapy, but since cancer is a heterogeneous disease, only few patients possibly respond to treatments. However, it opens a huge space for the advent of targeted therapies such as hormone therapy, immunotherapy, and target-specific drugs. Hormonal therapy using hormone agonists/antagonists or hormone receptor inhibitors-called the next-generation hormonal agents-hits distinct hormonal pathways that are involved in breast, prostate and ovarian cancer. Preliminary results show that through combination of drugs, it is possible that the synergistic effects may actually lead to better survival than with the use of single drugs. With manageable adverse effects, hormonal therapy offers much hope for treatment of this rather challenging malignancy of the hormone-sensitive cancers, especially in combination with other treatments.
Identifiants
pubmed: 39400627
doi: 10.1007/s12032-024-02517-z
pii: 10.1007/s12032-024-02517-z
doi:
Substances chimiques
Antineoplastic Agents, Hormonal
0
Hormones
0
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
283Informations de copyright
© 2024. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.
Références
Fact sheets by cancer. In: Global cancer observatory. International agency for research on cancer. 2024. https://gco.iarc.fr/today/en/fact-sheets-cancers . Accessed 14 Apr 2024.
Miki Y. Hormone-dependent cancers: new aspects on biochemistry and molecular pathology. Int J Mol Sci. 2023;24(13):10830. https://doi.org/10.3390/ijms241310830 .
doi: 10.3390/ijms241310830
pubmed: 37446008
pmcid: 10341538
Beavis A, Smith A, Fader AN. Lifestyle changes and the risk of developing endometrial and ovarian cancers: opportunities for prevention and management. Int J Womens Health. 2016;8:151–67. https://doi.org/10.2147/IJWH.S88367 .
doi: 10.2147/IJWH.S88367
pubmed: 27284267
pmcid: 4883806
Satpathi S, Gaurkar SS, Potdukhe A, Wanjari MB. Unveiling the role of hormonal imbalance in breast cancer development: a comprehensive review. Cureus. 2023;15(7):e41737. https://doi.org/10.7759/cureus.41737 .
doi: 10.7759/cureus.41737
pubmed: 37575755
pmcid: 10415229
Desai K, McManus JM, Sharifi N. Hormonal therapy for prostate cancer. Endocr Rev. 2021;42(3):354–73. https://doi.org/10.1210/endrev/bnab002 .
doi: 10.1210/endrev/bnab002
pubmed: 33480983
pmcid: 8152444
Törzsök P, Oswald D, Dieckmann KP, et al. Subsets of preoperative sex hormones in testicular germ cell cancer: a retrospective multicenter study. Sci Rep. 2023;13:14604. https://doi.org/10.1038/s41598-023-41915-7 .
doi: 10.1038/s41598-023-41915-7
pubmed: 37669975
pmcid: 10480169
Brian E. Henderson, heather spencer feigelson, hormonal carcinogenesis. Carcinogenesis. 2000;21(3):427–33. https://doi.org/10.1093/carcin/21.3.427 .
doi: 10.1093/carcin/21.3.427
Chen B, Ye P, Chen Y, Liu T, Cha JH, Yan X, Yang WH. Involvement of the estrogen and progesterone axis in cancer stemness: elucidating molecular mechanisms and clinical significance. Front Oncol. 2020;10:1657. https://doi.org/10.3389/fonc.2020.01657 .
doi: 10.3389/fonc.2020.01657
pubmed: 33014829
pmcid: 7498570
Zhao M. Mechanisms and therapeutic advances in the management of endocrine-resistant breast cancer. World J Clin Oncol. 2014;5(3):248. https://doi.org/10.5306/wjco.v5.i3.248 .
doi: 10.5306/wjco.v5.i3.248
pubmed: 25114842
pmcid: 4127598
Imamoto T, Suzuki H, Yano M, Kawamura K, Kamiya N, Araki K, Komiya A, Nihei N, Naya Y, Ichikawa T. The role of testosterone in the pathogenesis of prostate cancer. Int J Urol Off J Japanese Urol Association. 2008;15(6):472–80. https://doi.org/10.1111/j.1442-2042.2008.02074.x .
doi: 10.1111/j.1442-2042.2008.02074.x
Girling JS, Whitaker HC, Mills IG, Neal DE. Pathogenesis of prostate cancer and hormone refractory prostate cancer. J Urol Soc India. 2007;23(1):35–42. https://doi.org/10.4103/0970-1591.30265 .
doi: 10.4103/0970-1591.30265
Burstein HJ, Somerfield MR, Barton DL, Dorris A, Fallowfield LJ, Jain D, Johnston SRD, Korde LA, Litton JK, Macrae ER, Peterson LL, Vikas P, Yung RL, Rugo HS. Endocrine treatment and targeted therapy for hormone receptor-positive, human epidermal growth factor receptor 2-negative metastatic breast cancer: ASCO guideline update. J Clin Oncol Off J Am Soc Clin Oncol. 2021;39(35):3959–77. https://doi.org/10.1200/JCO.21.01392 .
doi: 10.1200/JCO.21.01392
Johnston S, Toi M, O’Shaughnessy J, Rastogi P, Campone M, Neven P, Huang C, Huober J, Jaliffe GG, Çiçin R, Tolaney SM, Goetz MP, Rugo HS, Senkus E, Testa L, Del Mastro L, Shimizu C, Wei R, Shahir A, Munoz M, San Antonio B, André V, Harbeck N, Martin M. Abemaciclib plus endocrine therapy for hormone receptor-positive, HER2-negative, node-positive, high-risk early breast cancer (monarchE): results from a preplanned interim analysis of a randomised, open-label, phase 3 trial. Lancet Oncol. 2023. https://doi.org/10.1016/s1470-2045(22)00694-5 .
doi: 10.1016/s1470-2045(22)00694-5
pubmed: 37146620
Musheyev D, Alayev A. Endocrine therapy resistance: what we know and future directions. Explor Targeted Anti-Tumor Ther. 2022. https://doi.org/10.37349/etat.2022.00096 .
doi: 10.37349/etat.2022.00096
Schierbeck LL, Rejnmark L, Tofteng CL, Stilgren L, Eiken P, Mosekilde L, et al. Effect of hormone replacement therapy on cardiovascular events in recently postmenopausal women: randomised trial. BMJ. 2012;345:e6409. https://doi.org/10.1136/bmj.e6409 .
doi: 10.1136/bmj.e6409
pubmed: 23048011
Lowenstein LM, Basourakos SP, Williams MD, Troncoso P, Gregg JR, Thompson TC, Kim J. Active surveillance for prostate and thyroid cancers: evolution in clinical paradigms and lessons learned. Nat Rev Clin Oncol. 2019;16(3):168–84. https://doi.org/10.1038/s41571-018-0116-x .
doi: 10.1038/s41571-018-0116-x
pubmed: 30413793
pmcid: 6501050
Lamplot JD, Denduluri S, Qin J, Li R, Liu X, Zhang H, Chen X, Wang N, Pratt A, Shui W, Luo X, Nan G, Deng ZL, Luo J, Haydon RC, He TC, Luu HH. The current and future therapies for human osteosarcoma. Curr Cancer Therapy Rev. 2013;9(1):55–77. https://doi.org/10.2174/1573394711309010006 .
doi: 10.2174/1573394711309010006
Derwahl M, Nicula D. Estrogen and its role in thyroid cancer. Endocr Relat Cancer. 2014;21(5):T273–83. https://doi.org/10.1530/ERC-14-0053 .
doi: 10.1530/ERC-14-0053
pubmed: 25052473
Li Y, Liu Q, He H, Luo W. The possible role of insulin-like growth factor-1 in osteosarcoma. Curr Probl Cancer. 2019;43(3):228–35. https://doi.org/10.1016/j.currproblcancer.2018.08.008 .
doi: 10.1016/j.currproblcancer.2018.08.008
pubmed: 30217668
Al-Shami K, Awadi S, Khamees A, Alsheikh AM, Al-Sharif S, Ala’ Bereshy R, Al-Eitan SF, Banikhaled SH, Al-Qudimat AR, Al-Zoubi RM, Al Zoubi MS. Estrogens and the risk of breast cancer: a narrative review of literature. Heliyon. 2023;9(9):e20224. https://doi.org/10.1016/j.heliyon.2023.e20224 .
doi: 10.1016/j.heliyon.2023.e20224
pubmed: 37809638
pmcid: 10559995
Goncharov AI, Maslakova AA, Polikarpova AV, Bulanova EA, Guseva AA, Morozov IA, Rubtsov PM, Smirnova OV, Shchelkunova TA. Progesterone inhibits proliferation and modulates expression of proliferation-Related genes in classical progesterone receptor-negative human BxPC3 pancreatic adenocarcinoma cells. J Steroid Biochem Mol Biol. 2017;165(Pt B):293–304. https://doi.org/10.1016/j.jsbmb.2016.07.007 .
doi: 10.1016/j.jsbmb.2016.07.007
pubmed: 27449817
Michaud JE, Billups KL, Partin AW. Testosterone and prostate cancer: an evidence-based review of pathogenesis and oncologic risk. Ther Adv Urol. 2015;7(6):378–87. https://doi.org/10.1177/1756287215597633 .
doi: 10.1177/1756287215597633
pubmed: 26622322
pmcid: 4647137
Davey RA, Grossmann M. Androgen receptor structure, function and biology: from bench to bedside. Clin Biochemist Rev. 2016;37(1):3–15.
Schiewer MJ, Augello MA, Knudsen KE. The AR dependent cell cycle: mechanisms and cancer relevance. Mol Cell Endocrinol. 2012;352(1–2):34–45. https://doi.org/10.1016/j.mce.2011.06.033 .
doi: 10.1016/j.mce.2011.06.033
pubmed: 21782001
Zhu ML, Kyprianou N. Androgen receptor and growth factor signaling cross-talk in prostate cancer cells. Endocr Relat Cancer. 2008;15(4):841–9. https://doi.org/10.1677/ERC-08-0084 .
doi: 10.1677/ERC-08-0084
pubmed: 18667687
pmcid: 2740735
Clusan L, Ferrière F, Flouriot G, Pakdel F. A basic review on estrogen receptor signaling pathways in breast cancer. Int J Mol Sci. 2023;24(7):6834. https://doi.org/10.3390/ijms24076834 .
doi: 10.3390/ijms24076834
pubmed: 37047814
pmcid: 10095386
Rugo HS, et al. Improving response to hormone therapy in breast cancer: new targets, new therapeutic options. Am Soc Clin Oncol Educ Book. 2016;36:e40–54.
doi: 10.1200/EDBK_159198
Cheung K. Endocrine therapy for breast cancer: an overview. Breast. 2007;16(4):327–43. https://doi.org/10.1016/j.breast.2007.03.004 .
doi: 10.1016/j.breast.2007.03.004
pubmed: 17499991
Brueggemeier RW, Anderson W. Ovarian suppression in the management of hormone receptor-positive breast cancer: current perspectives and recent advances. Endocr Relat Cancer. 2022;29(3):R155–66. https://doi.org/10.1530/ERC-22-0152 .
doi: 10.1530/ERC-22-0152
Cooper DS, Doherty GM, Haugen BR, Kloos RT, Lee SL, Mandel SJ, Mazzaferri EL, McIver B, Sherman SI, Tuttle RM, Taskforce ATAG. Management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid Off J Am Thyroid Association. 2006;16(2):109–42. https://doi.org/10.1089/thy.2006.16.109 .
doi: 10.1089/thy.2006.16.109
Haugen BR, Alexander EK, Bible KC, Doherty GM, Mandel SJ, Nikiforov YE, Pacini F, Randolph GW, Sawka AM, Schlumberger M, Schuff KG, Sherman SI, Sosa JA, Steward DL, Tuttle RM, Wartofsky L. 2015 American Thyroid Association Management Guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: The American Thyroid Association Guidelines task force on thyroid nodules and differentiated thyroid cancer. Thyroid Off J Am Thyroid Association. 2016;26(1):1–133. https://doi.org/10.1089/thy.2015.0020 .
doi: 10.1089/thy.2015.0020
Onklaas J, Bianco AC, Bauer AJ, Burman KD, Cappola AR, Celi FS, Cooper DS, Kim BW, Peeters RP, Rosenthal MS, Sawka AM, Force ATAT, on Thyroid Hormone Replacement,. Guidelines for the treatment of hypothyroidism: prepared by the American thyroid association task force on thyroid hormone replacement. Thyroid Off J Am Thyroid Association. 2014;24(12):1670–751. https://doi.org/10.1089/thy.2014.0028 .
doi: 10.1089/thy.2014.0028
Wu Y, Han Y, Yu P, Ouyang Q, Yan M, Wang X, Hu X, Jiang Z, Huang T, Tong Z, Wang S, Yin Y, Li H, Yang R, Yang H, Teng Y, Sun T, Cai L, Li H, Chen X, et al. Endocrine therapy for hormone receptor-positive advanced breast cancer: a Nation-Wide Multicenter Epidemiological Study in China. Front Oncol. 2021;10:599604. https://doi.org/10.3389/fonc.2020.599604 .
doi: 10.3389/fonc.2020.599604
pubmed: 33643905
pmcid: 7905089
Stathopoulos GP, Trafalis D, Kaparelou M. Bone metastasis in breast cancer is treated by high-dose tamoxifen. J BUON Off J Balkan Union Oncol. 2016;21(4):1013–5.
Kangas L, Unkila M. Tissue selectivity of ospemifene: pharmacologic profile and clinical implications. Steroids. 2013;78(12–13):1273–80. https://doi.org/10.1016/j.steroids.2013.09.003 .
doi: 10.1016/j.steroids.2013.09.003
pubmed: 24055829
Chumsri S, Howes T, Bao T, Sabnis G, Brodie A. Aromatase, aromatase inhibitors, and breast cancer. J Steroid Biochem Mol Biol. 2011;125(1–2):13–22. https://doi.org/10.1016/j.jsbmb.2011.02.001 .
doi: 10.1016/j.jsbmb.2011.02.001
pubmed: 21335088
pmcid: 3104073
Li Y, Hu W, Fu S, Li J, Liu J, Kavanagh J. Aromatase inhibitors in ovarian cancer: is there a role? Int J Gynecol Cancer. 2008;18(4):600–14. https://doi.org/10.1111/j.1525-1438.2007.01075.x .
doi: 10.1111/j.1525-1438.2007.01075.x
pubmed: 17894799
Mileshkin L, Edmondson R, O’Connell RL, Sjoquist KM, Andrews J, Jyothirmayi R, Beale P, Bonaventura T, Goh J, Hall M, Clamp A, Green J, Lord R, Amant F, Alexander L, Carty K, Paul J, Scurry J, Millan D, et al. Phase 2 study of anastrozole in recurrent estrogen (ER)/progesterone (PR) positive endometrial cancer: the PARAGON trial—ANZGOG 0903. Gynecol Oncol. 2019;154(1):29–37. https://doi.org/10.1016/j.ygyno.2019.05.007 .
doi: 10.1016/j.ygyno.2019.05.007
pubmed: 31130288
Argenta PA, Thomas SG, Judson PL, Downs LS, Geller MA, Carson LF, Jonson AL, Ghebre R. A phase II study of fulvestrant in the treatment of multiply-recurrent epithelial ovarian cancer. Gynecol Oncol. 2009;113(2):205–9. https://doi.org/10.1016/j.ygyno.2009.01.012 .
doi: 10.1016/j.ygyno.2009.01.012
pubmed: 19239974
Rugo HS. Elacestrant + targeted therapy for ER+/HER2– Metastatic breast Cancer: early phase trial findings. Targeted Oncol. 2024. https://www.targetedonc.com/view/elacestrant-targeted-therapy-for-er-her2--metastatic-breast-cancer-early-phase-trial-findings
Student S, Hejmo T, Poterała-Hejmo A, Leśniak A, Bułdak RJ. Anti-androgen hormonal therapy for cancer and other diseases. Eur J Pharmacol. 2020. https://doi.org/10.1016/j.ejphar.2019.172783 .
doi: 10.1016/j.ejphar.2019.172783
pubmed: 31712062
Kumar RJ, Barqawi A, Crawford ED. Adverse events associated with hormonal therapy for prostate cancer. Rev Urol. 2005;7(Suppl 5):S37–43.
pubmed: 16985883
pmcid: 1477613
Figg WD, Chau CH, Small EJ. Drug management of prostate cancer. New York: Springer; 2010.
doi: 10.1007/978-1-60327-829-4
Nelson CJ, Lee JS, Gamboa MC, Roth AJ. Cognitive effects of hormone therapy in men with prostate cancer: a review. Cancer. 2008;113(5):1097–106. https://doi.org/10.1002/cncr.23658 .
doi: 10.1002/cncr.23658
pubmed: 18666210
Studer UE, Whelan P, Albrecht W, Casselman J, de Reijke T, Hauri D, Loidl W, Isorna S, Sundaram SK, Debois M, Collette L. Immediate or deferred androgen deprivation for patients with prostate cancer not suitable for local treatment with curative intent: European Organisation for Research and Treatment of Cancer (EORTC) Trial 30891. J Clin Oncol Off J Am Soc Clin Oncol. 2006;24(12):1868–76. https://doi.org/10.1200/JCO.2005.04.7423 .
doi: 10.1200/JCO.2005.04.7423
Lam T, Birzniece V, McLean M, et al. The adverse effects of androgen deprivation therapy in prostate cancer and the benefits and potential anti-oncogenic mechanisms of progressive resistance training. Sports Med Open. 2020;6:13. https://doi.org/10.1186/s40798-020-0242-8 .
doi: 10.1186/s40798-020-0242-8
pubmed: 32056047
pmcid: 7018888
Hormone therapy for prostate Cancer fact sheet. 2021. Cancer. gov. https://www.cancer.gov/types/prostate/prostate-hormone-therapy-fact-sheet
Harbeck N, Rastogi P, Martín M, Tolaney SM, Shao Z, Fasching PA, Huang C, Jaliffe GG, Tryakin A, Goetz MP, Rugo HS, Senkus E, Testa L, Andersson M, Tamura K, Del Mastro L, Steger GG, Kreipe H, Hegg R, et al. Adjuvant abemaciclib combined with endocrine therapy for high-risk early breast cancer: updated efficacy and Ki-67 analysis from the monarchE study. Ann Oncol. 2021. https://doi.org/10.1016/j.annonc.2021.09.015 .
doi: 10.1016/j.annonc.2021.09.015
pubmed: 34756989
Meyer A, Sweeney CJ, Decker B. Targeting mTOR to overcome resistance to hormone and CDK4/6 inhibitors in breast cancer. Sci Rep. 2023;13(1):12345.
Olaparib: Uses, interactions, mechanism of action | DrugBank Online. (n.d.). DrugBank. https://go.drugbank.com/drugs/DB09074 Accessed 25 May 2024.
Lu YS, Im SA, Colleoni M, Franke F, Bardia A, Cardoso F, Harbeck N, Hurvitz S, Chow L, Sohn J, Lee KS, Campos-Gomez S, Villanueva Vazquez R, Jung KH, Babu KG, Wheatley-Price P, De Laurentiis M, Im YH, Kuemmel S, El-Saghir N, O’Regan R, Gasch C, Solovieff N, Wang C, Wang Y, Chakravartty A, Ji Y, Tripathy D. Updated overall survival of ribociclib plus endocrine therapy versus endocrine therapy alone in pre- and perimenopausal patients with HR+/HER2- advanced breast cancer in MONALEESA-7: A phase III randomized clinical trial. Clin Cancer Res. 2022;28(5):851–859. https://doi.org/10.1158/1078-0432.CCR-21-3032 .
doi: 10.1158/1078-0432.CCR-21-3032
Dhakal A, Antony Thomas R, Levine EG, Brufsky A, Takabe K, Hanna MG, Attwood K, Miller A, Khoury T, Early AP, Soniwala S, O’Connor T, Opyrchal M. Outcome of everolimus-based therapy in hormone-receptor-positive metastatic breast cancer patients after progression on palbociclib. Breast Cancer (Auckl). 2020;14:1178223420944864. https://doi.org/10.1177/1178223420944864 .
doi: 10.1177/1178223420944864
pubmed: 32753876
Clarke NW, Armstrong AJ, Thiery-Vuillemin A, Oya M, Shore N, Loredo E, Procopio G, De Menezes J, Girotto G, Arslan C, Mehra N, Parnis F, Brown E, Schlürmann F, Joung JY, Sugimoto M, Virizuela JA, Emmenegger U, Navratil J, et al. Abiraterone and olaparib for metastatic castration-resistant prostate cancer. NEJM Evid. 2022. https://doi.org/10.1056/evidoa2200043 .
doi: 10.1056/evidoa2200043
pubmed: 38319800
Saad F, De Bono J, Barthélémy P, Dorff T, Mehra N, Scagliotti G, Stirling A, Machiels J, Renard V, Maruzzo M, Higano CS, Gurney H, Healy C, Bhattacharyya H, Arondekar B, Niyazov A, Fizazi K. Patient-reported outcomes in men with metastatic castration-resistant prostate cancer harboring DNA damage response alterations treated with talazoparib: results from TALAPRO-1. Eur Urol. 2023;83(4):352–60. https://doi.org/10.1016/j.eururo.2022.05.030 .
doi: 10.1016/j.eururo.2022.05.030
pubmed: 35750582
Miller DS, Brady MF, Barrett RJ. A phase II trial of leuprolide acetate in patients with advanced epithelial ovarian carcinoma. A Gynecologic Oncology Group study. Am J Clin Oncol. 1992;15(2):125-8. https://doi.org/10.1097/00000421-199204000-00006 .
doi: 10.1097/00000421-199204000-00006
pubmed: 1553899
Khan OA, Gore M, Lorigan P, Stone J, Greystoke A, Burke W, Carmichael J, Watson AJ, McGown G, Thorncroft M, Margison GP, Califano R, Larkin J, Wellman S, Middleton MR. A phase I study of the safety and tolerability of olaparib (AZD2281, KU0059436) and dacarbazine in patients with advanced solid tumours. Br J Cancer. 2011;104(5):750–5. https://doi.org/10.1038/bjc.2011.8 .
doi: 10.1038/bjc.2011.8
pubmed: 21326243
pmcid: 3048218
Dilmac S, Ozpolat B. Mechanisms of PARP-inhibitor-resistance in BRCA-mutated breast cancer and new therapeutic approaches. Cancers. 2023;15(14):3642. https://doi.org/10.3390/cancers15143642 .
doi: 10.3390/cancers15143642
pubmed: 37509303
pmcid: 10378018
Agarwal N, Azad A, Shore ND, Carles J, Fay AP, Dunshee C, Karsh LI, Paccagnella ML, Di Santo N, Elmeliegy M, Lin X, Czibere A, Fizazi K. Talazoparib plus enzalutamide in metastatic castration-resistant prostate cancer: TALAPRO-2 phase III study design. Fut Oncol. 2022;18(4):425–36. https://doi.org/10.2217/fon-2021-0811 .
doi: 10.2217/fon-2021-0811
Warli SM, Velaro AJ, Firsty NN, Tala ZZ. Addition of olaparib to the new hormonal agent regimen for metastatic castration-resistant prostate cancer: a systematic review and meta-analysis. World J Oncol. 2023;14(6):518–28. https://doi.org/10.14740/wjon1685 .
doi: 10.14740/wjon1685
pubmed: 38022404
pmcid: 10681786
Mateo J, Porta N, Bianchini D, McGovern U, Elliott T, Jones R, Syndikus I, Ralph C, Jain S, Varughese M, Parikh O, Crabb S, Robinson A, McLaren D, Birtle A, Tanguay J, Miranda S, Figueiredo I, Seed G, Bertan C, et al. Olaparib in patients with metastatic castration-resistant prostate cancer with DNA repair gene aberrations (TOPARP-B): a multicentre, open-label, randomised, phase 2 trial. Lancet Oncol. 2020;21(1):162–74. https://doi.org/10.1016/S1470-2045(19)30684-9 .
doi: 10.1016/S1470-2045(19)30684-9
pubmed: 31806540
pmcid: 6941219
Moore K, Colombo N, Scambia G, Kim B, Oaknin A, Friedlander M, Lisyanskaya A, Floquet A, Leary A, Sonke GS, Gourley C, Banerjee S, Oza A, González-Martín A, Aghajanian C, Bradley W, Mathews C, Liu J, Lowe ES, et al. Maintenance olaparib in patients with newly diagnosed advanced ovarian cancer. N Engl J Med. 2018;379(26):2495–505. https://doi.org/10.1056/nejmoa1810858 .
doi: 10.1056/nejmoa1810858
pubmed: 30345884
de Bono JS, Mehra N, Scagliotti GV, Castro E, Dorff T, Stirling A, Stenzl A, Fleming MT, Higano CS, Saad F, Buttigliero C, van Oort IM, Laird AD, Mata M, Chen HC, Healy CG, Czibere A, Fizazi K. Talazoparib monotherapy in metastatic castration-resistant prostate cancer with DNA repair alterations (TALAPRO-1): an open-label, phase 2 trial. Lancet Oncol. 2021;22(9):1250–64. https://doi.org/10.1016/S1470-2045(21)00376-4 .
doi: 10.1016/S1470-2045(21)00376-4
pubmed: 34388386
Cuppone F, Bria E, Giannarelli D. Impact of hormonal treatment duration in combination with radiotherapy for locally advanced prostate cancer: meta-analysis of randomized trials. BMC Cancer. 2010;10:675. https://doi.org/10.1186/1471-2407-10-675 .
doi: 10.1186/1471-2407-10-675
pubmed: 21143897
pmcid: 3016294
Fastner G, Sedlmayer F, Widder J, Metz M, Geinitz H, Kapp K, Fesl C, Sölkner L, Greil R, Jakesz R, Kwasny W, Heck D, Bjelic-Radisic V, Balic M, Stöger H, Wieder U, Zwrtek R, Semmler D, Horvath W, Melbinger-Zeinitzer E, et al. Endocrine therapy with or without whole breast irradiation in low-risk breast cancer patients after breast-conserving surgery: 10-year results of the Austrian Breast and Colorectal Cancer Study Group 8A trial. Eur J Cancer (Oxford Engl 1990). 2020;127:12–20. https://doi.org/10.1016/j.ejca.2019.11.024 .
doi: 10.1016/j.ejca.2019.11.024
Ibrar M, Peddie N, Agnew S, Diserholt A, Fleming L. Breast cancer survivors’ lived experience of adjuvant hormone therapy: a thematic analysis of medication side effects and their impact on adherence. Front Psychol. 2022;13:861198. https://doi.org/10.3389/fpsyg.2022.861198 .
doi: 10.3389/fpsyg.2022.861198
pubmed: 35602711
pmcid: 9120958
Parkkari M, Paakkala AM, Salminen L, Holli K, Finnish Breast Cancer Group. Ocular side-effects in breast cancer patients treated with tamoxifen and toremifene: a randomized follow-up study. Acta Ophthalmol Scand. 2003;81(5):495–9. https://doi.org/10.1034/j.1600-0420.2003.00116.x .
doi: 10.1034/j.1600-0420.2003.00116.x
pubmed: 14510798
Pagani O, Regan MM, Walley BA, Fleming GF, Colleoni M, Láng I, Gomez HL, Tondini C, Burstein HJ, Perez EA, Ciruelos E, Stearns V, Bonnefoi HR, Martino S, Geyer CE Jr, Pinotti G, Puglisi F, Crivellari D, Ruhstaller T, Winer EP, International Breast Cancer Study Group, et al. Adjuvant exemestane with ovarian suppression in premenopausal breast cancer. New Engl J Med. 2014;371(2):107–18. https://doi.org/10.1056/NEJMoa1404037 .
doi: 10.1056/NEJMoa1404037
pubmed: 24881463
Files JA, Ko MG, Pruthi S. Managing aromatase inhibitors in breast cancer survivors: not just for oncologists. Mayo Clin Proc. 2010;85(6):560–6. https://doi.org/10.4065/mcp.2010.0137 .
doi: 10.4065/mcp.2010.0137
pubmed: 20511486
pmcid: 2878260
Mouridsen HT. Incidence and management of side effects associated with aromatase inhibitors in the adjuvant treatment of breast cancer in postmenopausal women. Curr Med Res Opin. 2006;22(8):1609–21. https://doi.org/10.1185/030079906X115667 .
doi: 10.1185/030079906X115667
pubmed: 16870085
Narayan V, Ross AE, Parikh RB, Nohria A, Morgans AK. How to treat prostate cancer with androgen deprivation and minimize cardiovascular risk. JACC CardioOncology. 2021;3(5):737–41. https://doi.org/10.1016/j.jaccao.2021.09.014 .
doi: 10.1016/j.jaccao.2021.09.014
pubmed: 34988484
pmcid: 8702790
Rhee H, Gunter JH, Heathcote P, Ho K, Stricker P, Corcoran NM, Nelson CC. Adverse effects of androgen-deprivation therapy in prostate cancer and their management. BJU Int. 2015;115(S5):3–13. https://doi.org/10.1111/bju.12964 .
doi: 10.1111/bju.12964
pubmed: 25327530
George A, McLachlan J, Tunariu N, et al. The role of hormonal therapy in patients with relapsed high-grade ovarian carcinoma: a retrospective series of tamoxifen and letrozole. BMC Cancer. 2017;17:456. https://doi.org/10.1186/s12885-017-3440-0 .
doi: 10.1186/s12885-017-3440-0
pubmed: 28666422
pmcid: 5493843